Text Size

Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites

This study has been completed.
Sponsor:
Information provided by:
Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT00115947
First received: June 26, 2005
Last updated: March 8, 2006
Last verified: June 2005
History of Changes
  Purpose

The purpose of this study is to investigate the effect of terlipressin on myocardial perfusion and renal function.

Hypothesis: Significant improvement of renal function reflected by: glomerular filtration rate (GFR), renal blood flow (RBF), excretion of salt and metabolites in the urine and related hormones and peptides in the blood. No effect on the systolic function of the heart.


Condition Intervention Phase
Cirrhosis
Ascites
 Drug: Terlipressin
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind

Resource links provided by NLM:

MedlinePlus related topics: Cirrhosis
U.S. FDA Resources

Further study details as provided by Hvidovre University Hospital:

Study Start Date: December 2004
Estimated Study Completion Date: January 2006
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Cirrhosis and ascites
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00115947

Locations
Denmark
Hvidovre Hospital
Copenhagen, Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
Investigators
Principal Investigator: Aleksander Krag Krag, MD Hvidovre Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00115947     History of Changes
Other Study ID Numbers: 2004-000568-29
Study First Received: June 26, 2005
Last Updated: March 8, 2006
Health Authority: Denmark: Danish Medicines Agency

Additional relevant MeSH terms:
Ascites
Liver Cirrhosis
Fibrosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
 Terlipressin
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents

ClinicalTrials.gov processed this record on May 21, 2013